Drug intelligence / Profile preview

CYWC628

Development stage: Phase 2
Lead developer: FibroBiologics
Modality: Cell Therapies
Administration: Topical

Overview

CYWC628 is an allogeneic fibroblast-based cell therapy consisting of fibroblast spheroids, developed by FibroBiologics for the treatment of diabetic foot ulcers (DFU). The therapy is designed to promote wound healing in chronic wounds by leveraging the regenerative properties of fibroblasts. FibroBiologics has established a manufacturing partnership with Charles River Laboratories for cGMP production of the therapeutic supply and cell banks. The company has also engaged Southern Star Research to manage a Phase 1/2 clinical trial in Australia, which is scheduled to commence in 2025.

Other names: fibroblast-based spheroids

Beyond the preview

Go deeper on CYWC628.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYWC628.

Explore the full profile